June 2026 in “World Journal of Urology” Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.
March 2026 in “European Urology Focus” Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.
January 2026 in “Springer Link (Chiba Institute of Technology)” Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
January 2026 in “Journal of Pharmacy & Bioresources” Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.
January 2026 in “E3S Web of Conferences” Silver nanoparticles from Mitracarpus scaber protect the liver and reduce prostate enlargement.
October 2025 in “University of Zadar Institutional Repository” Early hair loss may signal a risk for metabolic syndrome and related health issues.
October 2025 in “International Journal of Social health” Finasteride lowers PSA levels and prostate size, requiring adjusted PSA interpretation for accurate cancer screening.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
April 2025 in “Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )” Cuscuta reflexa extract may help treat benign prostatic hyperplasia by reducing inflammation and oxidative stress.